152 related articles for article (PubMed ID: 28060709)
1. The Enhancement of Nasal Drug Absorption From Powder Formulations by the Addition of Sodium Carboxymethyl Cellulose.
Tanaka A; Furubayashi T; Yamasaki H; Takano K; Kawakami M; Kimura S; Inoue D; Katsumi H; Sakane T; Yamamoto A
IEEE Trans Nanobioscience; 2016 Dec; 15(8):798-803. PubMed ID: 28060709
[TBL] [Abstract][Full Text] [Related]
2. Nasal Drug Absorption from Powder Formulations: Effect of Fluid Volume Changes on the Mucosal Surface.
Tanaka A; Furubayashi T; Enomura Y; Hori T; Shimomura R; Maeda C; Kimura S; Inoue D; Kusamori K; Katsumi H; Sakane T; Yamamoto A
Biol Pharm Bull; 2017; 40(2):212-219. PubMed ID: 28154262
[TBL] [Abstract][Full Text] [Related]
3. [Optimization of Nasal Drug Absorption from Powder Formulations: The Feasibility of Controlling Drug Absorption by the Use of Pharmaceutical Excipients].
Tanaka A
Yakugaku Zasshi; 2018; 138(12):1467-1472. PubMed ID: 30504659
[TBL] [Abstract][Full Text] [Related]
4. Nasal Absorption of Macromolecules from Powder Formulations and Effects of Sodium Carboxymethyl Cellulose on Their Absorption.
Tanaka A; Furubayashi T; Matsushita A; Inoue D; Kimura S; Katsumi H; Sakane T; Yamamoto A
PLoS One; 2016; 11(9):e0159150. PubMed ID: 27598527
[TBL] [Abstract][Full Text] [Related]
5. Nasal drug absorption from powder formulations: The effect of three types of hydroxypropyl cellulose (HPC).
Tanaka A; Furubayashi T; Tomisaki M; Kawakami M; Kimura S; Inoue D; Kusamori K; Katsumi H; Sakane T; Yamamoto A
Eur J Pharm Sci; 2017 Jan; 96():284-289. PubMed ID: 27664332
[TBL] [Abstract][Full Text] [Related]
6. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
Garmise RJ; Staats HF; Hickey AJ
AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
[TBL] [Abstract][Full Text] [Related]
7. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.
Gonçalves VSS; Matias AA; Poejo J; Serra AT; Duarte CMM
Int J Pharm; 2016 Dec; 515(1-2):1-10. PubMed ID: 27702697
[TBL] [Abstract][Full Text] [Related]
8. Influence of fillers in powder formulations containing N-acetyl-L-cysteine on nasal peptide absorption.
Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H
J Control Release; 2007 Jul; 120(1-2):88-94. PubMed ID: 17512076
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Estimation of the Effect of Nasal Mucociliary Function on in Vivo Absorption of Norfloxacin after Intranasal Administration to Rats.
Inoue D; Kimura S; Kiriyama A; Katsumi H; Yamamoto A; Ogawara KI; Higaki K; Tanaka A; Yutani R; Sakane T; Furubayashi T
Mol Pharm; 2018 Oct; 15(10):4462-4469. PubMed ID: 30165013
[TBL] [Abstract][Full Text] [Related]
10. Insoluble powder formulation as an effective nasal drug delivery system.
Ishikawa F; Murano M; Hiraishi M; Yamaguchi T; Tamai I; Tsuji A
Pharm Res; 2002 Aug; 19(8):1097-104. PubMed ID: 12240934
[TBL] [Abstract][Full Text] [Related]
11. Enhanced rectal and nasal absorption of human epidermal growth factor by combined use of the absorption promoter and the synthetic polymer in rats.
Murakami T; Kishimoto M; Kawakita H; Kisaki M; Kojima Y; Higashi Y; Amagase H; Fuwa T; Yata N
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():125-31. PubMed ID: 1820866
[TBL] [Abstract][Full Text] [Related]
12. Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent.
Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H
J Control Release; 2006 Oct; 115(2):183-8. PubMed ID: 16989920
[TBL] [Abstract][Full Text] [Related]
13. [Development of Prediction System for Drug Absorption after Intranasal Administration Incorporating Physiologic Functions of Nose -Estimation of in Vivo Drug Permeation through Nasal Mucosa Using in Vitro Membrane Permeability].
Inoue D
Yakugaku Zasshi; 2021; 141(11):1235-1240. PubMed ID: 34719543
[TBL] [Abstract][Full Text] [Related]
14. Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation.
Tas C; Ozkan CK; Savaser A; Ozkan Y; Tasdemir U; Altunay H
Drug Deliv; 2009 Apr; 16(3):167-75. PubMed ID: 19514977
[TBL] [Abstract][Full Text] [Related]
15. Opportunity and challenges of nasal powders: Drug formulation and delivery.
Tiozzo Fasiolo L; Manniello MD; Tratta E; Buttini F; Rossi A; Sonvico F; Bortolotti F; Russo P; Colombo G
Eur J Pharm Sci; 2018 Feb; 113():2-17. PubMed ID: 28942007
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity.
Ambrus R; Gieszinger P; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Janáky T; Tömösi F; Kecskeméti G; Szabó-Révész P; Bartos C
Molecules; 2020 Feb; 25(5):. PubMed ID: 32120992
[TBL] [Abstract][Full Text] [Related]
17. Improved nasal bioavailability of elcatonin by insoluble powder formulation.
Ishikawa F; Katsura M; Tamai I; Tsuji A
Int J Pharm; 2001 Aug; 224(1-2):105-14. PubMed ID: 11472819
[TBL] [Abstract][Full Text] [Related]
18. Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits.
Marttin E; Romeijn SG; Verhoef JC; Merkus FW
J Pharm Sci; 1997 Jul; 86(7):802-7. PubMed ID: 9232520
[TBL] [Abstract][Full Text] [Related]
19. Intranasal bioavailability of insulin powder formulations: effect of permeation enhancer-to-protein ratio.
Lee WA; Narog BA; Patapoff TW; Wang YJ
J Pharm Sci; 1991 Aug; 80(8):725-9. PubMed ID: 1791529
[TBL] [Abstract][Full Text] [Related]
20. Effect of viscous additives on drug absorption from the liver surface in rats using phenol red as a model.
Nishida K; Nakakoga Y; Sato N; Kawakami S; Mukai T; Sasaki H; Sakaeda T; Nakamura J
Eur J Pharm Biopharm; 2000 Nov; 50(3):397-402. PubMed ID: 11072197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
